GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (OTCPK:JWCTF) » Definitions » Current Deferred Revenue

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Current Deferred Revenue : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is JW (Cayman) Therapeutics Co Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

JW (Cayman) Therapeutics Co's current deferred revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.

JW (Cayman) Therapeutics Co Current Deferred Revenue Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Current Deferred Revenue Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial - - - - -

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

JW (Cayman) Therapeutics Co Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Business Description

Traded in Other Exchanges
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

JW (Cayman) Therapeutics Co (JW (Cayman) Therapeutics Co) Headlines

No Headlines